Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medical Cannabis Policy topic
No spam. Unsubscribe anytime.
Committee hears wide‑ranging OMMP and medical‑cannabis changes; employers and safety groups oppose employment‑related sections
Summary
Senate Bill 176 would overhaul parts of Oregon’s medical marijuana program, shifting some grow‑site oversight to the OLCC, lowering OHA card fees and adding anti‑discrimination protections for cardholders; employer groups and safety organizations urged deletion or revision of employment‑related sections they say conflict with federal rules and workplace safety needs.
Senate Bill 176 would remove certain Oregon Health Authority (OHA) oversight of registered grow‑site addresses, require digital medical‑marijuana registration cards, create an exclusive medical‑marijuana producer designation under the Oregon Liquor and Cannabis Commission (OLCC), and add anti‑discrimination measures for cardholders.
Anthony Taylor, legislative director for Compassionate Oregon and a member of the Oregon Cannabis Commission, described the bill as a major update to the medical program and said it would reduce OMMP administrative burdens, move growers who manage three or more patients to OLCC oversight, cap OHA card fees at $50 (down from as much as $200) and streamline renewals for people with debilitating conditions. "This bill is an effort to streamline the Oregon medical marijuana program and reduce its responsibilities to only cards," Taylor said.
The bill would also include protections preventing adverse employment actions based solely on a person's registered‑card status or a positive cannabis metabolite test if the use was lawful medical use; it would bar certain health‑care denials based solely on cardholder status.
Several employer and industry witnesses opposed sections 33–35, which create unemployment‑law protections and limits on employer drug testing. JL Wilson, representing the Oregon State Chamber of Commerce, said employers want to continue to enforce drug‑free workplace policies and cited Emerald Steel as precedent allowing employers to take action for federally prohibited drug use. Paloma Sparks (Oregon Business & Industry) said sections 33–35 would require employers to inquire into medical conditions and could leave employers unable to address safety risks. Drew Hagedorn (Associated General Contractors) and Jana Jarvis (Oregon Trucking Association) emphasized safety concerns on construction sites and for commercial drivers, citing federal drug and alcohol rules that prohibit marijuana for CDL holders (referencing 49 CFR Parts 40 and 382). Adrianne Anderson (Oregon School Boards Association) said school districts are concerned about CDL holders who transport students and the safety implications.
Senator McLean and others raised questions about proof of impairment and the phrase "reasonable suspicion" in the bill, and proponents and staff acknowledged the need for further work. Committee Chair Floyd Prozanski said the bill will receive additional drafting and that proponents and agencies should continue work with stakeholders.
Why it matters: The bill attempts to reconcile the state's medical program administration, reduce OHA workload, and strengthen patient protections, while creating tension with employers and federally regulated safety programs over workplace drug testing and reasonable‑suspicion standards.
What happens next: Committee members closed the public hearing and indicated that sections 33–35 will be a focus for further negotiations and drafting.
